Grant: Idea to Innovation
The University of British Columbia
$15,000.00
bWell-D Cognitive Assessment Platform for Depression: Market Assessment
FY 2024-25
Summary
This project will assess the market potential of bWell-D, an immersive virtual reality (VR) platform for comprehensive assessment of cognitive functioning in depression. Although cognitive deficits - difficulties with memory, attention and problem solving - are significant contributors to psychosocial impairment in depression, we lack tools that accurately assess cognitive functioning in real-world environments, or include emotionally based stimuli (such as receiving negative feedback or managing distractors) that can challenge individuals with depression. bWell-D was designed to measure cognitive performance in real-world environments, with specific attention to these cognitive and affective domains known to be affected in depression. bWell-D provides an individualized, detailed assessment report of cognitive functioning based on complex logged behavioural data. Brain activity via electroencephalography can also be measured during completion of bWell-D tasks, potentially informing our understanding of the underlying neural basis of functional impairment in depression.
In collaboration with Adventus Research and Consulting Inc., we will assess the market potential for this novel technology in 3 potential user groups: 1) care providers who would be interested in assessing and tracking treatment related changes in their client's cognitive functioning, 2) the pharmaceutical industry, which may use this tool to track cognitive functioning in all phases of novel drug development and 3) the academic sector interested in using this tool to investigate cognitive dysfunction in depression.
Program
Idea to Innovation
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
598120-2024
Name nom
Chakrabarty, Trisha T
Department département
Psychiatry
Organization id
2
Institution établissement
The University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
9027
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Mental Health
Research subject fr
Santé Mentale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
bWell-D Cognitive Assessment Platform for Depression: Market Assessment
Keywords
cognition; depression; diagnostics; virtual reality
Application summary
This project will assess the market potential of bWell-D, an immersive virtual reality (VR) platform for comprehensive assessment of cognitive functioning in depression. Although cognitive deficits - difficulties with memory, attention and problem solving - are significant contributors to psychosocial impairment in depression, we lack tools that accurately assess cognitive functioning in real-world environments, or include emotionally based stimuli (such as receiving negative feedback or managing distractors) that can challenge individuals with depression. bWell-D was designed to measure cognitive performance in real-world environments, with specific attention to these cognitive and affective domains known to be affected in depression. bWell-D provides an individualized, detailed assessment report of cognitive functioning based on complex logged behavioural data. Brain activity via electroencephalography can also be measured during completion of bWell-D tasks, potentially informing our understanding of the underlying neural basis of functional impairment in depression.
In collaboration with Adventus Research and Consulting Inc., we will assess the market potential for this novel technology in 3 potential user groups: 1) care providers who would be interested in assessing and tracking treatment related changes in their client's cognitive functioning, 2) the pharmaceutical industry, which may use this tool to track cognitive functioning in all phases of novel drug development and 3) the academic sector interested in using this tool to investigate cognitive dysfunction in depression.